TO ASSESS THE EFFECTS OF HYALURONIDASE WHEN USED AS WITH 0.25% BUPIVACAINE IN BRACHIAL PLEXUX BLOCK FOR ORTHOPAEDIC SURGERIES.
Phase 4
- Conditions
- Health Condition 1: S629- Unspecified fracture of wrist andhand
- Registration Number
- CTRI/2023/09/057190
- Lead Sponsor
- ESI-PGIMSR,JOKA,KOLKATA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Age 18 to 60 years.
2.Schedule for elective surgery of the upper
extremities.
3.Informed consent is given by the patients.
4.ASA physical status I & II.
Exclusion Criteria
1.Allergy to injection bupivacaine or
hyaluronidase.
2.Severe renal and hepatic disease.
3.Respiratory disease
4.Pulmonary and cardiac disease.
5.Neurologic, psychiatry disease.
6.Neuromuscular disease.
7.Pregnant or lactating women.
8.Morbid obesity.
9.Coagulation disorder cases.
10.Estimated surgical time duration more than
4 hours.
11.Unable to communicate.
12.Failure of peripheral nerve block
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reducing the time to reach complete sensory block while using injection hyluronidase as an adjuvants to injetion bupivacaine, so that the turnover time between operations can be reduced.Timepoint: approx one year
- Secondary Outcome Measures
Name Time Method a)To compare the safety and to compare the efficacy of hyaluronidase with 0.25% Bupivacaine against normal saline with 0.25% Bupivacaine.Timepoint: approx one year